GP-led secondaries and continuation vehicles: myths and realities
As we travel the world in search of investment opportunities, we encounter certain misperceptions about the continuation vehicle, an instrument for implementing general partner (GP)-led secondaries strategies. Continuation vehicles, or CVs, remain a misunderstood market innovation, and we address some of the most prevailing myths.
Myth 1
GP-led secondaries transactions are unfair to primary fund LPs since CVs are designed with only the GP’s goals in mind
Reality
Continuation vehicles (CVs) are designed as a liquidity mechanism that attempts to reconcile a GP’s desire to hold high-performing assets longer with the need of some limited partners (LPs) to achieve liquidity sooner. Both perspectives can be accommodated by presenting LPs with the option of either taking liquidity or rolling exposure into the new CV. Such interim liquidity options represent a positive development for outgoing investors, incoming investors, and the sponsor. Existing LPs achieve liquidity typically at multiples of their cost given the high-quality nature of the assets involved, and incoming investors gain exposure to assets poised to continue performing well over a multi-year horizon. Transparency, optionality, and a market-clearing pricing mechanism are critical to creating a win-win-win transaction for all parties.
Myth 2
Valuations aren’t set by the market, and CVs don’t achieve full value for legacy LPs
Reality
Most CVs price assets at or near the most recent net asset value (NAV) and often can price above the NAV depending on market conditions or the company’s performance. Most transactions are designed to achieve true market-clearing value by retaining an advisor to run an M&A-style process that includes price discovery from multiple secondaries funds or another sponsor; furthermore, third-party fairness opinions often are used as well. It’s important to remember that asset-level pricing includes underwriting multiple years of future appreciation and often the inclusion of new risk capital to support growth initiatives. We believe these factors help discipline the market and provide balance in risk/return evaluation for both existing LPs and future investors.
Myth 3
CVs frequently involve weaker, poorly performing tail-end assets that a sponsor can’t sell
Reality
In our view, today’s CVs almost always contain exposure to the highest quality assets in a sponsor’s portfolio. When GP-led secondaries started in earnest a decade ago, weakened sponsors were often seeking to relaunch their franchises or extend fund duration with lower-performing assets. Now strong sponsors across the world are viewing CVs as a portfolio management tool—an alternative on par with exits through an M&A or IPO. This evolution in exit planning allows a GP to evaluate all outcomes, including holding a high-performing asset longer and continuing to compound returns. Structural features demanded by the secondary market—including rolling any crystalized carry and original GP commitment and requiring a GP to invest new capital into the CV—all work to reinforce the notion that GPs create CVs with some of the highest quality assets the private equity market has to offer. In fact, from a risk/return perspective, this interim liquidity point might be considered an optimal time to participate in the potential appreciation of the asset.
Myth 4
Extra layers of fees associated with CVs depress returns
Reality
CV fees are lower than those for primary fund commitments and, more importantly, there are other factors far more influential to investment success in GP-led secondaries. Concentration demands higher investment hurdles, so the base underwriting cases are higher for CVs than for traditional LP secondaries. This, coupled with structural factors that provide GPs with an incentive to include high-performing assets, makes investment acumen matter much more than fee friction. Sourcing, underwriting, optimizing deal dynamics, and constructing a portfolio at a granular level afford a chance to achieve enhanced returns. Furthermore, from a risk/return perspective, a portfolio of CVs with manager continuity and the benefits of midlife investing presents an appealing opportunity to complement primary fund commitments, co-investments, and exposure to traditional LP secondaries investments.
Myth 5
CVs are simply co-investments with fees
Reality
Roughly half of CVs contain multiple assets and, by extension, are clearly different from co-investment transactions; however, even the remaining half of CVs—single-asset continuation vehicles—are quite distinct from co-investments. In a CV transaction, the sponsor is already a seasoned owner of the asset, affording the sponsor an intimate understanding of the company’s operations. All else being equal, the prospective risk of an asset a sponsor has long owned is materially lower than that of a new investment made by the sponsor for the first time.
Myth 6
CVs are a passing fad, fueled by the bull market bubble that itself has come to an end
Reality
The private markets have embraced CVs as a core transaction technique to achieve investor goals across the industry. Sponsors view CVs as a legitimate exit alternative for underlying fund assets, and many LPs have come to appreciate the opportunity to take intermediate-term liquidity, a feature even more relevant in today’s bear market. Investment banks and placement agents have staffed full teams to originate and advise on GP-led secondaries transactions in private equity with an emphasis on CVs. The advent of these types of transactions represents a secular shift in the market, not a cyclically induced bubble.
Final thoughts
GP-led secondaries—representing over half of the secondary market transaction volume the last two years—have proven to be a durable innovation, mutually beneficial for GPs, primary fund LPs, and new secondaries investors alike. GPs get to extend ownership of successful investments, existing LPs can take liquidity or stay invested, and new secondaries investors get to participate in the upside of seasoned, hard-to-access portfolio companies. Our view is that GP-led secondaries have become an essential function for private market participants of all types and deserve to be recognized for what they are—a vital portfolio management tool that balances the unique and nuanced needs of each participant in the transaction.
A widespread health crisis such as a global pandemic could cause substantial market volatility, exchange-trading suspensions and closures, and affect portfolio performance. For example, the novel coronavirus disease (COVID-19) has resulted in significant disruptions to global business activity. The impact of a health crisis and other epidemics and pandemics that may arise in the future could affect the global economy in ways that cannot necessarily be foreseen at the present time. A health crisis may exacerbate other preexisting political, social, and economic risks. Any such impact could adversely affect the portfolio’s performance, resulting in losses to your investment.
Investing involves risks, including the potential loss of principal. Financial markets are volatile and can fluctuate significantly in response to company, industry, political, regulatory, market, or economic developments. These risks are magnified for investments made in emerging markets. Currency risk is the risk that fluctuations in exchange rates may adversely affect the value of a portfolio’s investments.
The information provided does not take into account the suitability, investment objectives, financial situation, or particular needs of any specific person. You should consider the suitability of any type of investment for your circumstances and, if necessary, seek professional advice.
This material is intended for the exclusive use of recipients in jurisdictions who are allowed to receive the material under their applicable law. The opinions expressed are those of the author(s) and are subject to change without notice. Our investment teams may hold different views and make different investment decisions. These opinions may not necessarily reflect the views of Manulife Investment Management or its affiliates. The information and/or analysis contained in this material has been compiled or arrived at from sources believed to be reliable, but Manulife Investment Management does not make any representation as to their accuracy, correctness, usefulness, or completeness and does not accept liability for any loss arising from the use of the information and/or analysis contained. The information in this material may contain projections or other forward-looking statements regarding future events, targets, management discipline, or other expectations, and is only current as of the date indicated. The information in this document, including statements concerning financial market trends, are based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Manulife Investment Management disclaims any responsibility to update such information.
Neither Manulife Investment Management or its affiliates, nor any of their directors, officers or employees shall assume any liability or responsibility for any direct or indirect loss or damage or any other consequence of any person acting or not acting in reliance on the information contained here. All overviews and commentary are intended to be general in nature and for current interest. While helpful, these overviews are no substitute for professional tax, investment or legal advice. Clients should seek professional advice for their particular situation. Neither Manulife, Manulife Investment Management, nor any of their affiliates or representatives is providing tax, investment or legal advice. This material was prepared solely for informational purposes, does not constitute a recommendation, professional advice, an offer or an invitation by or on behalf of Manulife Investment Management to any person to buy or sell any security or adopt any investment strategy, and is no indication of trading intent in any fund or account managed by Manulife Investment Management. No investment strategy or risk management technique can guarantee returns or eliminate risk in any market environment. Diversification or asset allocation does not guarantee a profit or protect against the risk of loss in any market. Unless otherwise specified, all data is sourced from Manulife Investment Management. Past performance does not guarantee future results.
Manulife Investment Management
Manulife Investment Management is the global wealth and asset management segment of Manulife Financial Corporation. We draw on more than a century of financial stewardship to partner with clients across our institutional, retail, and retirement businesses globally. Our specialist approach to money management includes the highly differentiated strategies of our fixed-income, specialized equity, multi-asset solutions, and private markets teams—along with access to specialized, unaffiliated asset managers from around the world through our multimanager model.
This material has not been reviewed by, is not registered with any securities or other regulatory authority, and may, where appropriate, be distributed by the following Manulife entities in their respective jurisdictions. Additional information about Manulife Investment Management may be found at manulifeim.com/institutional
Australia: Manulife Investment Management Timberland and Agriculture (Australasia) Pty Ltd, Manulife Investment Management (Hong Kong) Limited. Brazil: Hancock Asset Management Brasil Ltda. Canada: Manulife Investment Management Limited, Manulife Investment Management Distributors Inc., Manulife Investment Management (North America) Limited, Manulife Investment Management Private Markets (Canada) Corp. Mainland China: Manulife Overseas Investment Fund Management (Shanghai) Limited Company. European Economic Area Manulife Investment Management (Ireland) Ltd. which is authorised and regulated by the Central Bank of Ireland Hong Kong: Manulife Investment Management (Hong Kong) Limited. Indonesia: PT Manulife Aset Manajemen Indonesia. Japan: Manulife Investment Management (Japan) Limited. Malaysia: Manulife Investment Management (M) Berhad 200801033087 (834424-U) Philippines: Manulife Investment Management and Trust Corporation. Singapore: Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration No. 200709952G) South Korea: Manulife Investment Management (Hong Kong) Limited. Switzerland: Manulife IM (Switzerland) LLC. Taiwan: Manulife Investment Management (Taiwan) Co. Ltd. United Kingdom: Manulife Investment Management (Europe) Ltd. which is authorised and regulated by the Financial Conduct Authority United States: John Hancock Investment Management LLC, Manulife Investment Management (US) LLC, Manulife Investment Management Private Markets (US) LLC and Manulife Investment Management Timberland and Agriculture Inc. Vietnam: Manulife Investment Fund Management (Vietnam) Company Limited.
Manulife, Manulife Investment Management, Stylized M Design, and Manulife Investment Management & Stylized M Design are trademarks of The Manufacturers Life Insurance Company and are used by it, and by its affiliates under license.
2629629
